A defining CVH moment in Europe: The Commission announced the Safe Hearts Plan
“When Europe acts together, we do not simply improve systems, we improve lives,” points out Benedetta Armocida, Coordinator of JACARDI, as the European Union’s Cardiovascular Health Plan is launched. At a time when cardiovascular disease remains Europe’s leading cause of death, this moment marks a collective step toward strengthening heart health across the continent.
Cardiovascular diseases (CVDs) remain the leading cause of death and disability in Europe, as confirmed by the newly released OECD report “The State of Cardiovascular Health in the European Union“. CVD claims 1.7 million lives each year, more than cancer and diabetes combined, and affects an estimated 62 million people. CVDs also contribute significantly to disability, early retirement, and absenteeism, lower the quality of life and reduce life expectancy, according to data from the European Commission [1], [2], [3].
The total economic burden of CVD in the EU is estimated at EUR 282 billion annually, around 2% of GDP, and significantly higher than that of cancer. The OECD report highlights stark geographic, gender and socio-economic disparities in cardiovascular outcomes and access to care, reinforcing the need for coordinated EU-level action. It also acknowledges JACARDI’s input to the report, and references JACARDI’s 4C Framework and pilot actions in France and Spain.
Bearing that in mind, the European Commission’s launch of the Cardiovascular Health Plan, under the name Safe Hearts Plan, marks a decisive moment for public health in the region. JACARDI strongly welcomes this Plan, as coordinated European action is essential to reduce the number of people falling ill with cardiovascular diseases, and to prevent premature deaths for those with existing conditions or risk factors, such as obesity, diabetes and high blood pressure.
“The launch of the Cardiovascular Health Plan marks a pivotal moment for Europe’s public health. JACARDI welcomes this initiative, recognizing the crucial role of Joint Actions in fostering collaboration among countries, experts, and stakeholders. By working together, sharing knowledge, and aligning efforts, we can ensure that advances in prevention, care, and innovation in cardiovascular health truly reach all communities, leaving no one behind,” notes Prof Graziano Onder, Scientific Coordinator of JACARDI.
The Plan arrives at a critical time. For too long, CVD and diabetes have lacked the political visibility their burden demands. The CVH Plan opens the door to a new European approach that puts prevention first, strengthens early detection and screening, and promotes equity and integrated, patient-centred care across health systems. For JACARDI, this initiative is an essential step towards making the healthy choice the easy and default choice for citizens across Europe.
“The CVH Plan is a decisive step forward, and JACARDI is proud to contribute with its experience and technical expertise. Our work shows that no cardiovascular strategy can be effective without putting equity at the centre, addressing the gaps linked to income, geography, education and gender that still shape health outcomes across Europe. We look forward to supporting the implementation of a Plan that has the potential to change lives across the region”, explains Dr Benedetta Armocida, coordinator of JACARDI.
The CVH Plan is needed as fragmented efforts can no longer address challenges that are inherently interconnected. “Prevention, early detection, treatment, rehabilitation, digital innovation, community engagement, these elements only create real impact when they are aligned and mutually reinforcing”, adds Dr Armocida.
Equally important is the improvement of data collection and use, ensuring that high-quality, reliable information drives policy decisions, guides clinical practice and allows progress to be measured transparently across countries, as highlighted in a recent policy paper published in The Lancet Regional Health – Europe, developed jointly by the Joint Action on Cardiovascular Diseases and Diabetes (JACARDI), the Joint Action Prevent Non-Communicable Diseases (JA PreventNCD), and the WHO Regional Office for Europe (WHO/Europe), [4].
“Robust and accessible data are essential to understand where inequalities arise, to identify people at risk earlier and to ensure timely, high-quality care across Europe. Strengthening data systems, from availability and quality to interoperability and sharing, is key to improving early detection, screening programmes and continuity of care”, says Dr Héctor Bueno, co-leader of the working group on data availability, quality, accessibility and sharing from JACARDI.
Through its multidisciplinary network, technical expertise and strong partnerships, JACARDI stands ready to support the successful rollout of the Safe Hearts Plan. The Joint Action will continue to contribute practical knowledge on prevention, governance, data systems and quality of care, building on lessons learned from other European health initiatives and aligning closely with the shared vision set out by the European cardiovascular community.
Joint Actions are more than projects, they are engines of collaboration. JACARDI can serve as a bridge between countries, stakeholders, and other EU initiatives, helping to translate the CVH Plan into coordinated, coherent, and sustainable action across Europe.
JACARDI is generating concrete insights on equity, early detection, integrated care, digital tools, data systems, and workforce capacity. These lessons, grounded in practice and validated across diverse health systems, can inform the plan’s priorities, standards, and operational frameworks. JACARDI remains fully committed to supporting the European Commission in prioritizing the Cardiovascular Health Plan and promoting its effective implementation across Member States, ensuring that every step forward translates into meaningful impact for people’s health.
The Safe Hearts Plan at a glance:
• Prioritises prevention as one of its main pillars
• Sets clear targets, including reducing mortality related to cardiovascular disease by 25% by 2035
• Encourages Member States to develop or implement national cardiovascular health plans by 2027
• Emphasises reducing health inequalities and improving access to healthcare
• Supports an EU protocol on health checks to shift the focus from treatment to prevention
• Addresses lifestyle risks, including unhealthy diets, ultra-processed foods, and smoking
Read the full European Commission Safe Hearts Plan here.
References:
[1] OECD (2025), The State of Cardiovascular Health in the European Union, OECD Publishing, Paris,
[2] Cardiovascular health; European Commission
[3] Fighting cardiovascular disease – a blueprint for EU action, June 2020. European Heart Network and the European Society of Cardiology.
[4] Benedetta Armocida, Hanna Tolonen, Ivo Rakovac, Beatrice Formenti, Jill Farrington, Allison Ekberg, Hector Bueno, Giovanni Capelli, Silvia Francisci, Morten S. Frydensberg, Ane Fullaondo, Linda Granlund, Yhasmine Hamu Azcarate, Torben F. Hansen, Emil Høstrup, Tomi Mäki-Opas, Luigi Palmieri, Markku Peltonen, Valentina Possenti, Marco Silano, Gundo Weiler, Kremlin Wickramasinghe, Edwin Wouters, Knut-Inge Klepp, Graziano Onder, Gauden Galea, Strengthening non-communicable diseases monitoring systems in Europe through a multistakeholder collaborative approach: a key priority for advancing data-driven policymaking, The Lancet Regional Health – Europe, Volume 61, 2026, 101553, ISSN 2666-7762,
A major step forward: Basque country rolls out integrated heart failure care model
A new pilot project has recently been launched in the Basque country as part of JACARDI, featuring an integrated, value-based care pathway for people with heart failure. This pilot is aligned with JACARDI’s broader mission to reduce the burden of cardiovascular disease and diabetes across Europe by strengthening coordinated care, enhancing health literacy, and scaling best practices.
Within JACARDI, Biosistemak represents the Basque country as an affiliated entity, co-leading communication and dissemination activities, supporting methodological frameworks for European pilots, contributing to health literacy initiatives, and leading the deployment of the heart failure pathway. This includes conducting a comprehensive needs assessment on the European level.
On 27 November, at the launch event organized at Cruces University Hospital in Barakaldo, Osakidetza – the public health care service of the Basque country – presented the new value-based integrated care pathway for heart failure, after two years of joint development with Biosistemak and Osakidetza’s Care Integration and Chronicity Service (SIAC). Throughout the entire development process, Biosistemak provided methodological support on pathway design, including the adaptation of care pathways and resources, the development of evaluation frameworks, the integration of technological requirements, and the preparation of awareness raising actions and training plans for professionals. The result is a comprehensive and coordinated care model that improves outcomes and quality of life for people living with heart failure while ensuring long-term sustainability.
During the event, Biosistemak researcher Yhasmine Hamu highlighted the importance of the extensive multidisciplinary collaboration behind the initiative. Over two years, professionals from family and community medicine, hospital care, nursing, pharmacy, and management collaborated to create a model that responds to real patient needs and incorporates sex- and gender-based perspectives. Presentations also highlighted innovative solutions, new corporate tools, and lessons learned on improving communication, standardising care, and defining indicators for continuous improvement.
The jointly developed pathway covers the entire care cycle for people with heart failure, from initial suspicion of the condition to hospitalisation, discharge, and ongoing follow-up in both primary and specialised settings. It is designed to align the perspectives of patients, professionals, and the general population. For patients, the model organises interventions and responsibilities in one integrated system to reduce morbidity and mortality and strengthen self-care. For professionals, it offers a clear overview of actions to be taken, decision-support tools, and a framework that promotes coordination and reduces variability. On a societal level, the model improves population health by enhancing scientific knowledge and reinforcing the sustainability of health systems.
The success of this pilot is a perfect example of how JACARDI supports Member States in adopting evidence-based and scalable care models for chronic disease management. Through its leadership in this initiative, Biosistemak contributes to strengthening integrated care and advancing cardiovascular health both within the Basque country and across Europe.
Can artificial intelligence help shape smarter cardiovascular policies across Europe?
What if policymakers across Europe had faster, clearer and more reliable data to guide decisions in cardiovascular health? Addressing that challenge, one of JACARDI’s pilot teams from CNIC presented their work at the ESC Digital & AI Summit 2025, showcasing AI innovations designed to turn evidence into actionable policy.
At the European Society of Cardiology Digital & AI Summit 2025, researchers Fatima Sanchez-Cabo, Juan Ignacio Alvarez Arenas, Daniel Jiménez Carretero, from the Computational Systems Biomedicine group at CNIC (Spanish Cardiovascular Research Center), and active members of JACARDI’s Working Group on Data Availability, Quality, Accessibility and Sharing, presented their poster: CARMINA: Optimizing low-parameter language models for high-quality cardiovascular research assistance. The work was featured in the session From bench to bedside: the potential roles of large language models in cardiovascular medicine, moderated by Professor Lis Neubeck, from Edinburgh Napier University; and Associate Professor Johan Verjans MD PhD FESC FRACP, from the University of Adelaide.
Why does this matter?
Within JACARDI’s Pilot 57, CNIC is developing EUROCARDIAB, a pioneering federated data platform integrating cardiovascular health indicators from across Europe. One of its key features is a CVD impact simulator that models how changes in risk factors could reduce event prevalence, providing policy makers with reliable, data-driven scenarios for national planning.
A dedicated web front-end will share these insights and will also host CARMINA (Cardiovascular And Research-driven Molecular Insight with Novel Assistant), an AI-powered research assistant designed to support specialized cardiovascular research. CARMINA will orchestrate the Intelligent Policy Agent (IPA), enabling autonomous trend analysis, computational modeling of interventions, and the creation of clear, actionable policy briefings for decision-makers in cardiology and diabetology.
This year’s ESC Digital & AI Summit motto, “Prepare for the next frontier in cardiovascular care”, aligns strongly with JACARDI’s overarching mission: accelerating patient outcomes and transforming clinical workflows across Europe through better data, smarter tools and more equitable care pathways.
Today, accurate, comparable and timely data on cardiovascular disease and diabetes remain limited, yet this information is essential for developing targeted policies that reduce disease burden, improve healthcare for all citizens and help close persistent inequalities.
The ESC Digital & AI Summit remains a key meeting point for global leaders, innovators and technology experts shaping the digital transformation of cardiovascular care, and pilots like this one from CNIC demonstrate how JACARDI is already turning that vision into meaningful, data-driven progress across Europe.
Mitja Lainscak: My hope is that we can intervene earlier for more patients
“It’s important that the JACARDI initiative and its outcomes gain visibility within the scientific community”, stresses Mitja Lainscak, Professor of Internal Medicine at the University of Ljubljana and member of JACARDI’s Scientific Advisory Board. As a clinical practitioner and researcher, he anticipates that collaboration will be one of the most important positive outcomes of the project, along with effects going from the regional or national level to the international level.
What significance does JACARDI hold for you and your organization?
I think that the organisations involved really appreciate being part of such a large initiative, trying to bring together efforts in the field of cardiovascular medicine and diabetes and to stimulate some potential cross-talk between the partners. The consortium is hosting more than 140 pilot projects with some of them related within or across the field.
One of the main benefits of an initiative like this, is that people talk to each other and realise that they can collaborate, so that their efforts can be transferred from the regional or national level to the international level.
How do you see JACARDI’s role in tackling the increasing prevalence of cardiovascular disease and diabetes in Europe?
Our society is aging and that’s an unavoidable reality. Advances in medicine have played a significant role in this trend. In addition, improvements in detection tools and the capabilities of our healthcare system have enhanced our ability to identify patients more effectively.
I hope we will identify more people at risk, as well as those with single or multiple conditions. Early detection is crucial because it allows us to start treatment earlier in the course of the disease, rather than waiting until it has progressed and caused irreversible damage. My hope is that we can intervene earlier for more patients.
How do you think JACARDI will influence future collaboration on cardiovascular disease and diabetes prevention in Europe?
JACARDI is a Joint Action, supported by the European Union and recognised by the scientific community. In a previous newsletter, I read a message from Professor Thomas F. Lüscher, the President of European Society of Cardiology highlighting the importance of JACARDI in shaping the future of cardiovascular disease and diabetes management through collaborative, data-driven care for the benefit of patients. I believe a similar message will come from the diabetes community. So, as said previously, having like-minded experts in the same room encourages discussion and cross-fertilisation of ideas. I anticipate that participants will begin to collaborate outside of the JACARDI framework, which I see as a positive outcome.
The European Society of Cardiology and the diabetes associations are already aligned, and I believe JACARDI has a crucial role to play in promoting future collaboration.
It’s important that the JACARDI initiative and its outcomes, such as pilot results, gain visibility in the scientific community. Researchers need to present their findings at conferences and submit their work for publication. This is essential to demonstrate that the funding received has been used effectively. Ultimately, it’s important to ensure that the investments made produce tangible results.
Based on your experience as a cardiologist, what do you consider the most critical factors in improving data-driven healthcare outcomes?
This is an extremely important question. Speaking from a national perspective, as someone from Slovenia, I’d like to extend this to an international context.
I believe that the lack of IT support for collecting data is a crucial issue. Slovenia is a small country with 2 million inhabitants and 14 hospitals, but we lack a unified IT system across these institutions. Although all hospitals are publicly owned and we have a single insurance provider, we struggle to collect comprehensive epidemiological data. We have a national hospitalization database, but it doesn’t give you the granularity of patient data.
The first necessary step would be the development of IT solutions, possibly using artificial intelligence, to extract the necessary data from medical records, particularly in terms of epidemiology. In my opinion, we still lack accurate figures for many diseases, both in Slovenia and across Europe.
Without this data, we cannot fully understand the scope of the problem, making it difficult to effectively allocate resources for patient management. I believe that the JACARDI pilots will showcase best practices in addressing this epidemiological data gap.
In terms of how JACARDI’s research and initiatives could support lasting, practical changes in clinical practice across Europe, particularly in Slovenia, I anticipate that most findings will primarily reflect the pilot country’s specific context . However, some lessons can be adapted across borders. Each country involved will focus on its specific challenges, but I believe that through meetings like this, where participants are encouraged to share their work, others can identify relevant lessons.
The perspective of the Advisory Board members is crucial in this process, as we aim to integrate ideas from different work packages that may not always communicate effectively with each other. This collaboration is essential.
Dr. Mitja Lainscak is a Professor of Internal Medicine at the University of Ljubljana and conducts clinical practice and research at the Department of Internal Medicine, General Hospital Murska Sobota, Slovenia. He is the Director of the Slovenian Research Agency and his clinical and research interest is cardiovascular medicine with particular emphasis on heart failure, pharmacotherapy, and metabolism with body composition. He has published more than 170 papers and holds an Executive Committee member position at the Heart Failure Association of the ESC.
Learn more about Mitja Lainscak and his work and connect on LinkedIn.
JACARDI’s synergies with Action Grants: reducing the cardiovascular burden together
The five Action Grants – CaregIVR, PERFECTO, Preventia, PROVIDE, RESIL-Card – and JACARDI are all anchored in the urgent mission of tackling the burden of cardiovascular diseases (CVD), Europe’s leading cause of death, which is especially timely as the European Commission develops the European Cardiovascular Health Plan (CVH Plan). This partnership is built upon the understanding that up to 80% of premature CVD deaths are preventable, and aims to strengthen cohesive EU-level action.
The overarching goal uniting JACARDI and these projects is the comprehensive reduction of the immense public health burden caused by Non-Communicable Diseases (NCDs), particularly Cardiovascular Diseases (CVD) and diabetes. This is pursued through a shared commitment to developing and promoting the implementation of validated best practices throughout the entire patient journey.
Within the implementation domain, projects focused on early detection, such as PERFECTO and PROVIDE, are collaborating with JACARDI WP8 to develop standardized screening protocols. Addressing health system continuity, RESIL-Card partners with JACARDI WP9 to specifically build resilience in cardiovascular care pathways, ensuring high-quality care continuity during crises.
Key expected outcomes include strengthening patient-centered approaches, utilizing novel digital tools like predictive algorithms by PROVIDE and immersive technology by CaregIVR, and developing tools such as the resilience assessment toolkit by RESIL-Card.
Synergies around equity are strengthened by sharing JACARDI’s “4Cs” Framework, which helps projects like CaregIVR and Preventia ensure targeted outreach to vulnerable populations. Both Preventia and PROVIDE showcase the central role of innovative digital tools in prevention efforts.
By coordinating our approach across technical work packages among these projects, we maximize collective impact and ensure that project outcomes translate effectively into actionable policy, creating roadmaps that support the scaling up of experiences at the national and regional levels.Ultimately, this unified collaboration contributes to promoting prevention, early detection, education, and sustained behavioral change for a healthier future.